Additionally, VEGFR inhibitors, such as Regorafenib and Cabozantinib, and PDGFR inhibitors, including Sunitinib, clustered with FLT3i, supporting their potential application in AML treatment. This evidence concerns the gene KDR and acute myeloid leukemia.